Literature DB >> 11882920

Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols.

Didier Cussac1, Adrian Newman-Tancredi, Yann Quentric, Nathalie Carpentier, Guillaume Poissonnet, Jean-Gilles Parmentier, Solo Goldstein, Mark J Millan.   

Abstract

Employing a novel, rapid and sensitive method for evaluation of phospholipase C (PLC) activity, the present study characterized the actions of diverse agonists and antagonists at human (h)5-HT2C receptors expressed in Chinese Hamster Ovary (CHO) cells. In addition, affinities and efficacies at these sites were compared with those obtained at h5-HT2B receptors.5-HT elicited a robust and rapid reduction in levels of the pre-labelled, membrane-bound substrate of PLC, [3H]phosphatidylinositols ([3H]PI). The time-course of [3H]PI depletion paralleled that of [3H]inositol phosphate ([3H]IP) accumulation, as determined by conventional anion exchange chromatography. Inactivation of h5-HT2C receptors with the alkylating agent, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), revealed a large receptor reserve, with half-maximal PLC activation induced by a concentration of 5-HT occupying only 5% of sites. In analogy to 5-HT ( Emax=100%), DOI, MK212 and mCPP, as well as the novel ligands, Ro600332, Ro600175 and BW723C86, showed "full" efficacy at h5-HT2C sites. Their efficacies were similar at h5-HT2B sites, with the exception of mCPP and MK212, which acted as partial agonists. Further, lisuride and Ro600869 behaved as partial agonists and antagonists at h5-HT2C and h5-HT2B receptors, respectively. As concerns functional selectivity (potency for induction of [3H]PI depletion), only Ro600175 preferentially activated h5-HT2B sites. In contrast, Ro600332 preferentially activated h5-HT2C receptors. Amongst antagonists, RS102221 and SB242084 displayed a marked preference for h5-HT2C sites, whereas LY266097, S33526 and SB204741 behaved as selective antagonists at h5-HT2B receptors. At both h5-HT2C and h5-HT2B receptors, antagonist potency (p Kb) and binding affinity (p Ki) were highly correlated. In conclusion, this rapid and innovative method for determination of PLC activity permitted characterization of an extensive range of novel ligands at h5-HT2C receptors. Although several antagonists clearly differentiated h5-HT2C from h5-HT2B receptors under these conditions, highly selective agonists remain to be identified.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882920     DOI: 10.1007/s00210-001-0505-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  23 in total

Review 1.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.

Authors:  Clint E Canal; Drake Morgan
Journal:  Drug Test Anal       Date:  2012-04-19       Impact factor: 3.345

2.  Stimulation of medial prefrontal cortex serotonin 2C (5-HT(2C)) receptors attenuates cocaine-seeking behavior.

Authors:  Nathan S Pentkowski; Felicia D Duke; Suzanne M Weber; Lara A Pockros; Andrew P Teer; Elizabeth C Hamilton; Kenneth J Thiel; Janet L Neisewander
Journal:  Neuropsychopharmacology       Date:  2010-06-02       Impact factor: 7.853

3.  Discriminative stimulus effects of serotonin agonists, neutral antagonists, and inverse agonists in pigeons: perspectives on intrinsic efficacy measurements in vivo.

Authors:  Martilias Farrell; Sharon Rosenzweig-Lipson; Ellen Walker
Journal:  Psychopharmacology (Berl)       Date:  2010-06-05       Impact factor: 4.530

4.  Selective serotonin 5-HT(2C) receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues.

Authors:  Kathryn A Cunningham; Robert G Fox; Noelle C Anastasio; Marcy J Bubar; Sonja J Stutz; F Gerard Moeller; Scott R Gilbertson; Sharon Rosenzweig-Lipson
Journal:  Neuropharmacology       Date:  2011-05-11       Impact factor: 5.250

5.  Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.

Authors:  Dhwanil A Dalwadi; Seongcheol Kim; Shahnawaz M Amdani; Zhenglan Chen; Ren-Qi Huang; John A Schetz
Journal:  Pharmacol Res       Date:  2016-05-06       Impact factor: 7.658

6.  Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.

Authors:  B Schaerlinger; P Hickel; N Etienne; L Guesnier; L Maroteaux
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

7.  Behavioral, pharmacological and neuroanatomical analysis of serotonin 2C receptor agonism on maternal behavior in rats.

Authors:  Ruiyong Wu; Jun Gao; Shinnyi Chou; Collin Davis; Ming Li
Journal:  Psychoneuroendocrinology       Date:  2016-08-16       Impact factor: 4.905

8.  Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes.

Authors:  Mark J Millan; Sylvie Veiga; Sylvie Girardon; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

Review 9.  Chronic treatment with anti-bipolar drugs causes intracellular alkalinization in astrocytes, altering their functions.

Authors:  Dan Song; Baoman Li; Enzhi Yan; Yi Man; Marina Wolfson; Ye Chen; Liang Peng
Journal:  Neurochem Res       Date:  2012-07-28       Impact factor: 3.996

10.  Serotonin (5-HT) receptor 2b activation augments glucose-stimulated insulin secretion in human and mouse islets of Langerhans.

Authors:  Hedvig Bennet; Inês G Mollet; Alexander Balhuizen; Anya Medina; Cecilia Nagorny; Annika Bagge; Joao Fadista; Emilia Ottosson-Laakso; Petter Vikman; Marloes Dekker-Nitert; Lena Eliasson; Nils Wierup; Isabella Artner; Malin Fex
Journal:  Diabetologia       Date:  2016-01-06       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.